Centre for Drug Misuse Research, 19 Keith Street, Glasgow, G11 6QQ.
J Subst Abuse Treat. 2013 Jan;44(1):97-102. doi: 10.1016/j.jsat.2012.04.003. Epub 2012 Jun 15.
The focus of drug policy in the UK has shifted markedly in the past 5 years to move beyond merely emphasising drug abstinence towards maximising individuals' opportunities for recovery. The UK government continues to recognise the prescribing of narcotic medications indicated for opiate dependence as a key element of these individuals' recovery journey. This article describes a small, naturalistic comparison of the efficacy of the two most commonly prescribed opiate substitute medications in the UK--methadone hydrochloride (methadone oral solution) and Suboxone (buprenorphine-naloxone sublingual tablets)--for reducing current heroin users' (n = 34) days of heroin use, and preventing short-term abstainers (n = 37) from relapsing to regular heroin use. All patients had been prescribed either methadone or Suboxone for maintenance for 6 months prior to intake. Results showed that when controlling for a number of patient-level covariates, both methadone and Suboxone significantly reduced current users' days of heroin use between the 90 days prior to intake and at the 8-month follow-up, with Suboxone yielding a significantly larger magnitude reduction in heroin use days than methadone. Methadone and Suboxone were highly and equally effective for preventing relapse to regular heroin use, with all but 3 of 37 (91.9%) patients who were abstinent at intake reporting past 90-day point prevalence heroin abstinence at the 8-month follow-up. Overall, prescribing methadone or Suboxone for eight continuous months was highly effective for initiating abstinence from heroin use, and for converting short-term abstinence to long-term abstinence. However, the study design, which was based on a relatively small sample size and was not able randomise patients to medication and so could not control for the effects of potential prognostic factors inherent within each patient group, means that these conclusions can only be made tentatively. These positive but preliminary indications of the comparative efficacy of methadone and Suboxone for treating opiate dependence now require replication in a well-powered, randomised controlled trial.
英国的药物政策重点在过去 5 年中发生了明显变化,不再仅仅强调戒毒,而是转向最大限度地提高个人康复机会。英国政府继续承认为阿片类药物依赖开具麻醉药物处方是这些人康复过程的关键要素。本文描述了在英国最常开的两种阿片类替代药物(盐酸美沙酮(美沙酮口服液)和丁丙诺啡纳洛酮舌下片(Suboxone))的疗效进行了小型、自然的比较,以减少当前海洛因使用者(n=34)的海洛因使用天数,并防止短期戒断者(n=37)重新开始使用常规海洛因。所有患者在入组前都已接受美沙酮或 Suboxone 维持治疗 6 个月。结果表明,在控制了一些患者水平的协变量后,美沙酮和 Suboxone 都显著减少了入组前 90 天和 8 个月随访期间当前使用者的海洛因使用天数,Suboxone 使海洛因使用天数的减少幅度明显大于美沙酮。美沙酮和 Suboxone 对预防恢复常规海洛因使用非常有效,入组时保持戒断的 37 名患者中,除 3 名(91.9%)外,其余患者在 8 个月随访时报告过去 90 天海洛因点患病率为戒断。总体而言,连续 8 个月开美沙酮或 Suboxone 对开始戒断海洛因非常有效,并将短期戒断转化为长期戒断。然而,由于该研究设计基于相对较小的样本量,无法对患者进行药物随机分组,因此无法控制每个患者组中固有的潜在预后因素的影响,因此只能得出暂定的结论。这些关于美沙酮和 Suboxone 治疗阿片类药物依赖的相对疗效的积极但初步的结果现在需要在一项有足够效力的随机对照试验中得到复制。